Table 1.
Summary of characteristics of glioma samples
| Sample | Sex | Age (at sugery) |
Histological type | Grade | Mutation status | % tumor cells |
|---|---|---|---|---|---|---|
| TRAINING COHORT | ||||||
| 13-01 | F | 28 | Ependymoma | 2 | IDHwt | * |
| 13-02 | M | 40 | Astrocytoma | 3 | IDH1-R132H | 70 |
| 13-03 | M | 58 | Oligodendroglioma | 3 | IDH1-R132H | 70 |
| 13-04 | V | 62 | Glioblastoma | 4 | IDHwt | 60 |
| 13-05 | M | 56 | Metastasis | ** | IDHwt | * |
| 13-06 | M | 53 | Oligodendroglioma | 3 | IDH2-R172K | 60 |
| 13-07 | F | 20 | Variant glioma | 2 | IDHwt | * |
| 13-08 | M | 67 | Glioblastoma | 4 | IDHwt | 70 |
| 13-09 | V | 58 | Glioblastoma | 4 | IDHwt | 70 |
| 13-10 | M | 45 | Oligodendroglioma | 3 | IDH1-R132H | 65 |
| 13-11 | V | 67 | Glioblastoma | 4 | IDHwt | 70 |
| 13-13 | M | 52 | Glioblastoma | 4 | IDH1-V178I | 70 |
| 13-14 | F | 64 | Glioblastoma | 4 | IDHwt | 70 |
| 13-15 | V | 44 | Oligodendroglioma | 3 | IDH1-R132H | 50 |
| 13-16 | M | 60 | Glioblastoma | 4 | IDHwt | 70 |
| 13-17 | M | 45 | Oligodendroglioma | 2 | IDH1-R132H | 50 |
| 13-18 | V | 49 | Oligodendroglioma | 3 | IDH1-R132H | 50 |
| 14-01 | V | 52 | Glioblastoma | 4 | IDHwt | 80 |
| 14-02 | M | 43 | Oligodendroglioma | 2 | IDH1-R132H | 50 |
| 14-03 | V | 62 | Glioblastoma | 4 | IDHwt | 70 |
| 14-04 | M | 72 | Glioblastoma | 4 | IDHwt | 60 |
| 14-05 | M | 21 | Astrocytoma | 2 | IDH1-R132H | 70 |
| 14-06 | M | 43 | Oligodendroglioma | 3 | IDH1-R132H | 50 |
| 14-07 | M | 65 | Oligodendroglioma | 3 | IDH1-R132H | 50 |
| 14-08 | M | 50 | Astrocytoma | 3 | IDH1-R132H | 50 |
| 14-09 | V | 43 | Astrocytoma | 3 | IDH1-R132H | 60 |
| 14-10 | V | 45 | Glioblastoma | 4 | IDH1-R132H | 50 |
| 14-11 | M | 50 | Glioblastoma | 4 | IDHwt | 60 |
| 14-12 | M | 59 | Oligodendroglioma | 3 | IDH1-R132H | 50 |
| 14-13 | M | 39 | Pleomorphous xanthoastrocytoma | 3 | IDHwt, BRAF-V600E | 70 |
| 15-01 | M | 66 | Glioblastoma | 4 | IDHwt | 50 |
| 15-02 | V | 61 | Glioblastoma | 4 | IDHwt | 70 |
| 15-03 | V | 76 | Glioblastoma | 4 | IDHwt | 40 |
| 15-04 | V | 59 | Glioblastoma | 4 | IDHwt | 40 |
| 15-05 | M | 31 | Astrocytoma | 3 | IDH1-R132H | 70 |
| 15-06 | V | 49 | Astrocytoma | 3 | IDH1-R132H/V178I | 70 |
| 15-07 | M | 63 | Glioblastoma | 4 | IDH1-V178I | 65 |
| 15-08 | M | 55 | Astrocytoma | 2 | IDH1_R132H | 60 |
| 15-09 | M | 70 | Glioblastoma | 4 | IDHwt | 70 |
| 15-10 | V | 68 | Oligodendroglioma | 3 | IDH1-R132H | 70 |
| 15-11 | M | 33 | LPD | ** | IDHwt | * |
| 15-12 | M | 46 | Glioblastoma | 4 | IDHwt | 70 |
| 15-13 | V | 78 | Glioblastoma | 4 | IDHwt | 80 |
| 15-14 | M | 79 | Glioblastoma | 4 | IDHwt | 70 |
| 15-15 | V | 58 | Glioblastoma | 4 | IDHwt | 70 |
| 15-16 | M | 25 | Astrocytoma | 2 | IDH1-R132H/V178I | 50 |
| 15-17 | M | 68 | Glioblastoma | 4 | IDHwt | 60 |
| 15-18 | V | 64 | Glioblastoma | 4 | IDHwt | 70 |
| 16-01 | M | 61 | Glioblastoma | 4 | IDHwt | 70 |
| 16-02 | M | 47 | Glioblastoma | 4 | IDHwt | 70 |
| 16-03 | V | 46 | Astrocytoma | 3 | IDH1-R132H | 25 |
| 16-04 | M | 59 | Oligodendroglioma | 3 | IDH1-R132H | 60 |
| 16-05 | M | 51 | Glioblastoma | 4 | IDHwt | 50 |
| 16-06 | V | * | Astrocytoma | * | IDH1-R132H | 50 |
| 16-07 | M | 74 | Glioblastoma | 4 | IDH1-Y183C | 60 |
| 16-08 | F | 68 | Glioblastoma | 4 | IDHwt | 50 |
| 16-09 | V | 49 | Glioblastoma | 4 | IDHwt | 70 |
| 16-10 | M | * | Astrocytoma | * | IDH1-R132H | 60 |
| 16-11 | M | 67 | Glioblastoma | 4 | IDHwt | 50 |
| 16-12 | M | 23 | Astrocytoma | 3 | IDH1-R132H | 60 |
| 16-13 | M | 60 | Glioblastoma | 4 | IDHwt | 70 |
| 16-14 | V | 60 | Oligodendroglioma | 3 | IDH2-R172M | 70 |
| 16-15 | V | 61 | Oligodendroglioma | 3 | IDH1-R132H | 70 |
| 16-16 | M | 58 | Glioblastoma | 4 | IDH1-V178I | 40 |
| 16-17 | V | 18 | Oligodendroglioma | 2 | IDH2-R172K | 40 |
| 16-18 | * | 30 | Oligodendroglioma | 3 | IDH2-R172W | 70 |
| 16-19 | M | 48 | Glioblastoma | 4 | IDHwt | 70 |
| 17-01 | M | 58 | Oligodendroglioma | 2 | IDH1-R132H | 50 |
| 17-02 | M | 40 | Astrocytoma | 3 | IDH1-R132H/V178I | 70 |
| 17-03 | V | 76 | Glioblastoma | 4 | IDHwt | 65 |
| 17-04 | M | 42 | Oligodendroglioma | 3 | IDH1-R132H | 70 |
| 17-05 | M | 59 | Glioblastoma | 4 | IDHwt | 70 |
| 17-06 | M | 65 | Glioblastoma | 4 | IDHwt | 70 |
| 17-07 | M | 63 | Glioblastoma | 4 | IDHwt | 70 |
| 17-08 | F | 26 | DNET | 1 | IDHwt | * |
| VALIDATION COHORT | ||||||
| 17-09 | F | 67 | Glioblastoma | 4 | IDHwt | * |
| 17-10 | F | 67 | Astrocytoma | 2 | IDH1-R132H | * |
| 17-11 | M | 67 | 4 | IDHwt | * | |
| 17-12 | * | * | IDH1-V178I | * | ||
| 17-13 | F | 59 | Glioblastoma | 4 | IDHwt | 75 |
| 17-14 | M | 46 | Oligodendroglioma | 2 | IDH1-R132H | * |
| 17-16 | M | 56 | Astrocytoma | 3 | IDH1-R132H | * |
| 18-01 | F | 48 | oligodendroglioma | 2 | IDH1-R132H | 60 |
| 18-02A | F | 39 | Astrocytoma | 2 | IDHwt | * |
| 18-02B | F | 44 | Astrocytoma | 2 | IDHwt | * |
| 18-04 | M | 65 | Glioblastoma | 4 | IDHwt | 65 |
| 18-05 | M | 19 | Astrocytoma | 3 | IDHwt | 45 |
| 18-06 | M | 48 | Glioblastoma | 4 | IDHwt | 70 |
| 18-07 | M | 76 | Glioblastoma | 4 | IDHwt | * |
| 18-08 | M | 69 | unknown | IDHwt | 45 | |
| 18-09 | M | 39 | Astrocytoma | 3 | IDH1-R132H | 80 |
| 18-10 | M | 53 | Glioblastoma | 4 | IDHwt | 80 |
| 18-12 | M | 51 | oligodendroglioma | 2 | IDH1-R132H | few |
| 18-13 | M | 42 | Pleomorphous xanthoastrocyoma | 3 | BRAF-V600E | * |
| 18-14 | M | 53 | Other | IDHwt | 40 | |
| 18-15 | M | 67 | Glioblastoma | 4 | IDHwt | 65 |
| 18-16 | M | 76 | Glioblastoma | 4 | n.d. | 70 |
| 18-17 | F | 45 | Oligodendroglioma | 2 | IDH1-R132H | 70 |
| 18-18 | F | 72 | Glioblastoma | 4 | n.d. | 75 |
| 18-19 | M | 55 | Glioblastoma | 4 | 80 | |
| 18-20 | F | 54 | Glioblastoma | 4 | IDH1-V178I | 80 |
| 18-21 | M | 53 | Other | 4 | IDHwt | 75 |
| 18-23 | 80 | |||||
Histological type, WHO grade, and percentage tumor cells were confirmed by a trained neuropathologist (B.K.). IDH-mutational status was derived from the t/RNA-seq data. All IDH1-R132H/IDH2 mutations were validated by routine diagnostic genetic analysis with the ‘Radboud Cancer Hotspot Gene panel’.
Abbreviations: DNET Dysembryoplastic neuroepithelial tumor, F Female, IDH Isocitrate dehydrogenase, LPD Lymphoproliferative disorder, M Male, IDHWT Wild-type, WHO World Health Organization. * data not available; ** non-glioma, no WHO-grade